CN201171818Y - Protein circulation absorption filtration system - Google Patents
Protein circulation absorption filtration system Download PDFInfo
- Publication number
- CN201171818Y CN201171818Y CNU2007200589613U CN200720058961U CN201171818Y CN 201171818 Y CN201171818 Y CN 201171818Y CN U2007200589613 U CNU2007200589613 U CN U2007200589613U CN 200720058961 U CN200720058961 U CN 200720058961U CN 201171818 Y CN201171818 Y CN 201171818Y
- Authority
- CN
- China
- Prior art keywords
- albumen
- circulation
- filter
- protein liquid
- throughput
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- External Artificial Organs (AREA)
Abstract
The utility model relates to an albumen circulation adsorption filter system, which comprises an albumen dialysis circulation part and an albumen liquid depuration regeneration circulation part, and is mainly characterized in that a low-throughput dialyzer in the MARS albumen liquid depuration regeneration circulation part is substituted by a high-throughput filter; an active carbon adsorber and a resin adsorber are connected on the albumen liquid outlet end of the high-throughput filter in series; a filter film in the high-throughput filter is a copolymerization film made by taking a polymer of propylene and novalgin as material; the average aperture of the film is 178 nm. The albumen circulation adsorption filter system uses the high-throughput filter to carry out pre-purification to albumen liquid, greatly lightens burden of later active carbon adsorber and the resin adsorber, and makes the active carbon adsorber and the resin adsorber can maintain adsorption capacity for a long time and the entire system can effectively eliminate various inflammation genes, inflammation mediums, toxins, etc. in blood. Compared with an MARS system, the albumen circulation adsorption filter system can obtain good treatment effect in treating severe disease such as multiple organ dysfunction syndromes, and the like.
Description
Technical field
This utility model relates to blood purification system, particularly adopts the blood purification system of albumen dialysis technology.
Background technology
Adopt the basic structure of the blood purification system of albumen dialysis technology, comprise albumen dialysis circulation and protein liquid purifying regeneration circulation two parts.Its ultimate principle is to utilize protein liquid as dialysis solution in albumen dialysis circulation, makes in the blood samples of patients and lps molecule protein bound toxin and other type, transfers in the protein liquid by dialyzer, and blood is purified; Meanwhile, the circulation of protein liquid purifying regeneration purifies contaminated protein liquid, and protein liquid can be reused.This blood purification system based on albumen dialysis technology is the ideal blood purification system of present clean-up effect, and wherein the MARS system that produces with German Teraklin company especially maintains the leading position.Yet, find in the clinical treatment that existing this type systematic does not often reach ideal therapeutic effect when being used for the treatment of the more multiple organ dysfunction patient of vivotoxin.Find that after deliberation main cause wherein is, the protein liquid purifying regeneration cyclic part of existing this type systematic uses the small throughput dialyser, the small throughput dialyser only gives molecular weight less than 15000 little lps molecule, molecular weight still is deposited in the protein liquid at the big or middle lps molecule more than 15000, these are deposited in the big or middle lps molecule in the protein liquid, all transfer to active carbon and resin adsorbs together with the protein binding toxin in the protein liquid.When system is used for the treatment of general diseases, do not have obvious problem, but when being used for the treatment of diseases such as multiple organ dysfunction syndrome when system, because patient's vivotoxin is more, the lps molecule of not removed by the small throughput dialyser that is deposited in the systematic protein liquid significantly increases, be easy to make active carbon and resin that the absorbability of protein binding toxin is reached capacity, and protein binding toxin can only rely on active carbon and resin absorption to remove basically, so finally have influence on the blood purification effect of whole system.
Summary of the invention
The purpose of this utility model provides a kind of novel blood purification system: albumen circulation absorption filtration system, and in the hope of obtaining more ideal effect aspect the diseases such as treatment multiple organ dysfunction syndrome.
This utility model is achieved in that albumen circulation absorption filtration system comprises albumen dialysis circulation and protein liquid purifying regeneration circulation two parts, wherein protein liquid purifying regeneration cyclic part comprises active carbon adsorber and resin absorption device, also include the high flux filter especially, substituted the small throughput dialyser in the MARS protein liquid purifying regeneration cyclic part, active carbon adsorber and resin absorption device are connected on the protein liquid port of export of high flux filter, be provided with filter membrane in the high flux filter, described filter membrane is that the polymer with propylene and methanesulfonic sodium is the combined polymerization film that material is made, and the average pore size of film is 178nm.Because the average pore size of filter membrane is 178nm, so the molecular weight in the protein liquid can both pass through filter membrane at the middle or small lps molecule 40000 below, and from the discarded liquid outlet discharge of high flux filter; On the other hand, because the used material of filter membrane can show negative charge characteristic in solution, therefore filter membrane also has very strong adsorption, molecular weight in the adsorbable protein liquid is at the big lps molecule more than 40000, above characteristics make the burden of follow-up active carbon and resin greatly alleviate, active carbon and resin are not prone to saturated, active carbon and resin absorbability can be kept for a long time, thereby better effect can be obtained aspect the diseases such as treatment multiple organ dysfunction syndrome protein binding toxin.
The utility model has the advantages that: the filter membrane in the high flux filter has hydrophilic and hydrophobic segment, has guaranteed the wet strength of the permeability and the film of solute; Owing to improved protein liquid purifying regeneration circulation clean-up effect, so whole system can more effectively be removed various inflammatory factors in the blood, inflammatory mediator, toxin etc.With the MARS systematic comparison, this system can obtain better therapeutic effect aspect the seriously diseases such as treatment multiple organ dysfunction syndrome.
Description of drawings
Fig. 1 is the structural representation of this utility model embodiment;
Fig. 2 is the structural representation of the high flux filter among Fig. 1.
The specific embodiment
Referring to Fig. 1, albumen circulation described in the utility model is adsorbed the filtration system and is comprised albumen dialysis circulation and protein liquid purifying regeneration circulation two parts.Albumen dialysis circulation comprises albumen dialyser 3 and pump 2.The circulation of protein liquid purifying regeneration comprises high flux filter 4, pump 5, absorbent charcoal adsorption tank 6 and resin absorption jar 7.Referring to Fig. 2, the structure of high flux filter 4 comprises a housing 10, housing is provided with protein liquid outlet 11, protein liquid inlet 12 and discarded liquid outlet 13, enclosure interior is provided with many hollow fiber conduits 14, hollow fiber conduit 14 is communicated with the protein liquid gateway 11,12 of housing, constitute the inner chamber of high flux filter, the enclosure interior space beyond the hollow fiber conduit 14 constitutes the exocoel of high flux filter, and exocoel is communicated with discarded liquid outlet 13.The tube wall of hollow fiber conduit 14 constitutes the filter membrane between exocoel and the inner chamber.The tube wall of hollow fiber conduit 14 is that the polymer with propylene and methanesulfonic sodium is the combined polymerization film that material is made, and the average pore size of film is 178nm.This combined polymerization film can adopt commercially available finished product, for example the AN69 film of Zinpro Corp.'s production.
The operation principle of present embodiment is described below in conjunction with Fig. 1 and Fig. 2: patient's blood passes through albumen dialyser 3 from top to bottom under the driving of pump 2, and the blood after the purification is failed back and given the patient.Be provided with dialyzer in albumen dialyser 3 inside, the dialyzer both sides are respectively mobile blood and protein liquid (normally albumin liquid), the large, medium and small molecule metabolites matter of the protein binding toxin in the blood and other type is transferred in the protein liquid through dialyzer, and blood is purified.Contaminated protein liquid enters high flux filter 4 under the driving of pump 5.In high flux filter 4 inside, protein liquid flows in hollow fiber conduit 14.Molecular weight in the protein liquid arrives the exocoel of depurator by the tube wall of hollow fiber conduit 14 at the middle or small lps molecule below 40000, and discharge from discarded liquid outlet 13 and to import waste collection jar 8, molecular weight in the protein liquid is at the big lps molecule more than 40000, for example the tumor necrosis factor that exists with tetramer form is attracted on the tube wall of hollow fiber conduit 14.Pass through absorbent charcoal adsorption tank 6, resin absorption jar 7 adsorption treatment more successively from high flux filter 4 effusive protein liquids, the lps molecule of the protein binding toxin in the removal protein liquid and other residual type, the protein liquid that has purified at last is back to the exocoel of albumen dialyser 3.
As further improvement, present embodiment also is parallel with displacement liquid feeder 9 at the protein liquid port of export of high flux filter 4.The displacement liquid that displacement liquid feeder 9 is provided enters the exocoel of albumen dialyser 3 with protein liquid.By regulating the solute concentration of displacement liquid, the flow-rate ratio of perhaps regulating displacement liquid and discarded liquid can reach the therapeutical effect of regulating patient's water, electrolyte, acid-base balance.For example the potassium ion in the blood samples of patients is on the low side, can provide high potassium displacement liquid by displacement liquid feeder 9, make displacement liquid enter the exocoel of albumen dialyser 3 with the protein liquid after purifying, potassium ion in the displacement liquid enters blood through the dialyzer of albumen dialyser 3, improves the concentration of potassium ion in the blood samples of patients with this.
Claims (2)
1, the filtration system is adsorbed in a kind of albumen circulation, comprise albumen dialysis circulation and protein liquid purifying regeneration circulation two parts, wherein the circulation of protein liquid purifying regeneration comprises active carbon adsorber and resin absorption device, it is characterized in that: the circulation of protein liquid purifying regeneration also includes the high flux filter, active carbon adsorber and resin absorption device are connected on the protein liquid port of export of high flux filter, be provided with filter membrane in the high flux filter, described filter membrane is that the polymer with propylene and methanesulfonic sodium is the combined polymerization film that material is made, and the average pore size of film is 178nm.
2, the filtration system is adsorbed in albumen circulation as claimed in claim 1, and it is characterized in that: the protein liquid port of export of high flux filter is parallel with the displacement liquid feeder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007200589613U CN201171818Y (en) | 2007-10-31 | 2007-10-31 | Protein circulation absorption filtration system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007200589613U CN201171818Y (en) | 2007-10-31 | 2007-10-31 | Protein circulation absorption filtration system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201171818Y true CN201171818Y (en) | 2008-12-31 |
Family
ID=40198928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2007200589613U Expired - Fee Related CN201171818Y (en) | 2007-10-31 | 2007-10-31 | Protein circulation absorption filtration system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201171818Y (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732771B (en) * | 2009-12-17 | 2011-08-17 | 中日友好医院 | Cell reactor and artificial liver support system comprising same |
-
2007
- 2007-10-31 CN CNU2007200589613U patent/CN201171818Y/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732771B (en) * | 2009-12-17 | 2011-08-17 | 中日友好医院 | Cell reactor and artificial liver support system comprising same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2092944B1 (en) | Electrosorption device for the purification of blood and other fluids | |
| EP2446908B1 (en) | Electrosorption and decomposition device for the purification of blood and other fluids | |
| AU2013349977B2 (en) | Liver support system | |
| US9713668B2 (en) | Multi-staged filtration system for blood fluid removal | |
| AU2013349975B2 (en) | Integrated device for liver support system | |
| JP2010507464A (en) | Liquid-saving cascade hemofiltration | |
| CN201033178Y (en) | Novel external artificial liver supporting and treating system | |
| CN101041092A (en) | Multiple organ dysfunction and support system | |
| CN201123923Y (en) | Mixed type artificial liver system capable of for curing multiple-organ dysfunctional syndrome | |
| CN203507201U (en) | Separating type hemodialysis absorber | |
| WO2019167441A1 (en) | Toxin separator | |
| CN104117104A (en) | Integrated blood purification device with blood perfusion structure and blood dialysis structure | |
| CN205073379U (en) | Plasma exchange adsorbs filters clean system | |
| CN201171818Y (en) | Protein circulation absorption filtration system | |
| CN203354984U (en) | Plasma exchange adsorption filtration purification system for preparing square plasma storage pond | |
| CN109794172B (en) | Preparation method of antibacterial hollow fiber membrane for blood purification | |
| CN107569730A (en) | A kind of device applied to haemodialysis | |
| CN203280813U (en) | Plasma exchange absorption filtering purifying system provided with plasma storage bag in matched mode | |
| CN201026322Y (en) | Multiple organ functions support system | |
| CN203139198U (en) | Simple blood purifier | |
| CN203989183U (en) | The apparatus for purifying blood of integrated strip hemoperfusion and hemodialysis structure | |
| EP1935441A1 (en) | Device for the removal of toxic substances from blood | |
| CN208552666U (en) | A kind of plasma exchange dialysis adsorption system | |
| CN115461100A (en) | Fluid treatment method and circulation treatment equipment and system | |
| CN103263706A (en) | Plasma storage bag special for plasma exchange, absorption, and filtration treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081231 Termination date: 20121031 |